Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A Profit Margin

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A (FBIOP) currently reports a profit margin of 184.98% as of March 2026. That compares with -79.19% in the prior-year period — up 333.6% year over year. That is above the Healthcare sector average of 14.34%. Use the charts on this page to explore Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's profit margin history and peer comparisons.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's profit margin increased from -79.19% to 184.98% — a 333.6% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's profit margin of 184.98% is higher than the Healthcare sector average of 14.34%. That is roughly 1189.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's current 184.98% should be judged against Healthcare norms (sector average: 14.34%) and against FBIOP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 184.98%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A, and consider following FBIOP for alerts when major investors trade the stock.